Topiramate: Safety in migraine patients

Topiramate, a sulfa-derivative monosaccharide was originally developed as a hypoglycemic agent, but was found to be devoid of hypoglycemic activity, and later, it was approved in 1995 in the UK as adjunctive treatment for partial-onset seizures.1 Topiramate with several mechanisms of actions, by its long half-life, high oral bioavailability, low protein binding, renal elimination, and with little or no hepatic metabolism, proves to be an ideal migraine prophylaxis medication, and was approved in 2004 by the Food and Drug Administration.2,3…..